Defibrillators news | Breaking defibrillators news | Defibrillators

UPDATE 2-Boston Scientific net falls on Guidant costs

...Boston Scientific said sales of drug-coated stents in the quarter were weaker than it expected as physicians referred fewer patients for the procedure after a widely publicized study found stents offered no advantage over medication in preventing heart attacks and death for some patients.

Sales of implantable cardioverter The results were "pretty much in line with relatively modest expectations," said Leerink Swann analyst Jason Wittes.

"Stents were so-so.

They continue to slide in line with what we would expect, given the J&J numbers." Boston Scientific competes in the stent market against Johnson & Johnson (JNJ.N: Quote, Profile , Research), which last week reported a 27 percent drop in sales of its Cypher drug-coated stent.

Continued...

© Reuters 2007.

All Rights Reserved.

3 Next > FACT BOX STJ.N Last: Change: Up/Down: Quote Full Chart Company Profile Analyst Research Loading...

QUOTES by Name by Symbol AstraZeneca pays high price to join vaccines race More Shares News...

Reuters.co.uk: Help Careers International Editions: Africa ...

Read more...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news